Related references
Note: Only part of the references are listed.CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies
Hildur Helgadottir et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II-III) Astrocytomas
Gerald F. Reis et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
Histologic features of melanoma associated with CDKN2A genotype
Michael R. Sargen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study
Chunan Bian et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2015)
The Loss of p16 Expression Worsens the Prognosis of OSCC
Mario Perez-Sayans et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant
Thomas P. Potjer et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2015)
Cyclin D1, p16INK4A and p27Kip1 in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis
Despoina Georgiadou et al.
APMIS (2014)
Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery
I. El-Mokadem et al.
BRITISH JOURNAL OF CANCER (2014)
Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier
Thomas Knoesel et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
Abdlsattar Zebary et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass
Johan Staaf et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
Hildur Helgadottir et al.
JOURNAL OF MEDICAL GENETICS (2014)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
The Degree of Segmental Aneuploidy Measured by Total Copy Number Abnormalities Predicts Survival and Recurrence in Superficial Gastroesophageal Adenocarcinoma
Jon M. Davison et al.
PLOS ONE (2014)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Emmi Peurala et al.
BREAST CANCER RESEARCH (2013)
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma
Sandra Rebouissou et al.
JOURNAL OF PATHOLOGY (2012)
Risk of Non-Melanoma Cancers in First-Degree Relatives of CDKN2A Mutation Carriers
Bhramar Mukherjee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients
Ilaria Iacobucci et al.
CLINICAL CANCER RESEARCH (2011)
Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A
Jasper I. van der Rhee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Expression of p16INK4a, Alone or Combined With p53, is Predictive of Better Prognosis in Colorectal Adenocarcinoma in Tunisian Patients
Imen Miladi-Abdennadher et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
Fabrice Jardin et al.
BLOOD (2010)
Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study
F. Demenais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Veronica Hoiom et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families
Femke A. de Snoo et al.
CLINICAL CANCER RESEARCH (2008)
Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome:: Results of a Swedish preventive program
Johan Hansson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
E Grafström et al.
CLINICAL CANCER RESEARCH (2005)
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families
Å Borg et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
